Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

ANI Pharmaceuticals ( (ANIP) ) just unveiled an update.

The trial subjects were adults with either type 1 or type 2 diabetes, exhibiting central involvement in diabetic macular ...

An update from ANI Pharmaceuticals ( (ANIP) ) is now available.

ANI Pharmaceuticals (ANIP) stock drops as its Iluvien implant fails in a clinical trial versus Eylea marketed by Regeneron ...

In ANI's New Day trial, patients were randomized to an induction phase to receive either a single Iluvien injection or a series of five monthly injections of aflibercept, followed by supplemental ...

ANI Pharmaceuticals (ANIP) announced results from the NEW DAY clinical trial of ILUVIEN, or fluocinolone acetonide intravitreal implant, 0.19 mg ...

Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the ...

15 th March 2025 – Alimera Sciences Limited, an ANI Pharmaceuticals, Inc. Company, today announced an update to the Summary of Product Characteristics (SmPC) for ILUVIEN 190 micrograms intravitreal ...

ILUVIEN is contraindicated for patients with certain ocular infections, glaucoma with high cup to disc ratios, and known hypersensitivity to any of the product’s components. The updated label includes ...

ILUVIEN now approved for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) in addition to diabetic macular edema (DME) ANI plans to begin ...

ILUVIEN is contraindicated for patients with certain ocular infections, glaucoma with high cup to disc ratios, and known hypersensitivity to any of the product’s components.